World Toll Like Receptor 4 (CD284 or TLR4) Pipeline Review 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016" report to their offering.

Toll Like Receptor 4 (CD284 or TLR4) pipeline Target constitutes close to 36 molecules. Out of which approximately 32 molecules are developed by Companies and remaining by the Universities/Institutes. The author's latest report Toll Like Receptor 4 - Pipeline Review, H1 2016, outlays comprehensive information on the Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Toll Like Receptor 4 (CD284 or TLR4) Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL). The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 7, 2, 19 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Furthermore, this report also reviews key players involved in Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Toll Like Receptor 4 Overview
  3. Therapeutics Development
  4. Pipeline Products for Toll Like Receptor 4 - Overview
  5. Pipeline Products for Toll Like Receptor 4 - Comparative Analysis
  6. Toll Like Receptor 4 - Therapeutics under Development by Companies
  7. Toll Like Receptor 4 - Therapeutics under Investigation by Universities/Institutes
  8. Toll Like Receptor 4 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Toll Like Receptor 4 - Products under Development by Companies
  13. Toll Like Receptor 4 - Products under Investigation by Universities/Institutes
  14. Toll Like Receptor 4 - Companies Involved in Therapeutics Development
  • Batu Biologics, Inc.
  • BioLineRx, Ltd.
  • Biomedica Management Corporation
  • Eisai Co., Ltd.
  • eTheRNA Immunotherapies NV
  • Formune S.L.
  • GlaxoSmithKline Plc
  • Harbor Therapeutics, Inc.
  • Immune Design Corp.
  • Immunovo BV
  • Kyorin Pharmaceutical Co., Ltd.
  • NovImmune SA
  • Reliance Life Sciences Pvt. Ltd.
  • TaiwanJ Pharmaceuticals Co., Ltd.
  • Vascular Biogenics Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/545255/toll_like

Related Topics: Immune Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716